Kevin M. Pantalone, DO

Dr. Pantalone has received local and national media attention for research pertaining to adverse outcomes with sulfonylurea therapy.   He has served as the Director of Clinical Research for the Department of Endocrinology, Diabetes & Metabolism at Cleveland Clinic from 2014-2019.   His research is regularly featured in Healio Endocrine today, https://www.healio.com/endocrinology.  His commentary on recently published studies pertaining to diabetes is featured regularly by Endocrinology Advisor, https://www.endocrinologyadvisor.com/.  He is a member of MD Magazine’s Advisory Board, and serves on numerous institutional, ADA, and AACE committees.

• Endocrine Certification in Neck Ultrasound (ECNU)

• Co-presenter, Busting Inertia: Identifying and Engaging High Risk Patients, Overcoming Therapeutic Inertia Webinar, American Diabetes Association, September 2020.
• Appointed Section Editor, Primary Care and Public Health, Journal of the American Osteopathic Association, August 2020
• Appointed to the Ohio Diabetes Action Plan 2021 Advisory Committee, 2020-2021
• Appointed to the American Association of Clinical Endocrinologists (AACE)/American College of Endocrinology (ACE) Clinical Practice Guideline Conflict of Interest Subcommittee, 2020-present
• Appointed to the American Association of Clinical Endocrinologists (AACE)/American College of Endocrinology (ACE) Clinical Practice Guideline Conflict of Interest Subcommittee Clinical Practice Guidelines Strategic Planning Task Force, 2020-present
• Principal Investigator for SOUL: A Heart Disease Study of Semaglutide in Patients With Type 2 Diabetes
• Principal Investigator for SURPASS-CVOT: A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes
• Appointed as Vice-Chair of the Appointed to the American Association of Clinical Endocrinologists (AACE)/American College of Endocrinology (ACE) Clinical Practice Guideline Oversight Committee, 2020
• Activity Director, VJ Canizaro, MD Health Summit, Traditional Medical City, Biloxi, MS, March 2020
• Awarded The Emotionally Intelligent Leadership Certificate from Case Western Reserve University Weatherhead School of Management, December 2019
• Nominated by institutional leadership to complete the annual “Lead Forward, Transforming Enterprise” leadership course at Cleveland Clinic, November 4-9, 2019
• Appointed to the Endocrine Self-Assessment Program (ESAP) Faculty Working Group, 2019
• Appointed to the American Diabetes Association Therapeutic Inertia Research Work Group, 2019
• Appointed as Director of Diabetes Initiatives, Endocrinology and Metabolism Institute, August, 2019
• Invited to the American Diabetes Association Summit on Therapeutic Inertia, November 2018.This Summit, organized to identify and assess issues related to therapeutic inertia, brought together over 100 members of the diabetes healthcare ecosystem, including interprofessional primary care providers, diabetes specialists, health systems, payors and patient advocacy groups.
• Appointed member of the steering committee for NN8022-4432, An Obesity Pragmatic Clinical Trial, 2018.
• Appointed to the American College of Endocrinology Task Force to serve as a member of the ACE CPG Oversight Committee, 2018-2020.
• Nominated by department leadership to complete the “Introduction to Emotional Intelligence” course at the Case Western Reserve Weatherhead School of Management, July, 2018.
• Featured regularly by Endocrinology Advisor, providing commentary on recently published studies pertaining to diabetes, 2017 to present. https://www.endocrinologyadvisor.com/
• Appointed to Research Executive Committee, Cleveland Clinic, 2017 to present
• Research Information Technology Advisory Board, Cleveland Clinic, 2017 to present
• Appointed to Patient Access Steering Committee, Cleveland Clinic, 2017 to present
• Member of MD Magazine’s Advisory Board, 2017 to present
• Principal Investigator for PIONEER-6: A Trial Investigating the Cardiovascular Safety of Oral Semaglutide in Subjects with Type 2 Diabetes
• Appointed to the American College of Endocrinology (College) Task Force to Update the AACE Growth Hormone Clinical Practice Guidelines, 2017-2020
• Appointed to the American College of Endocrinology (College) to serve as a member of the ACE Scientific Referencing Team (ASRT), 2016-2018
• Research regularly featured in Healio Endocrine today. https://www.healio.com/endocrinology
• Research Featured in Endocrine News, September 2016.The Endocrine Society. https://endocrinenews.endocrine.org/wp-content/uploads/EN0916_ROW.pdf
• Featured regularly on Cleveland Clinic’s Consult QD, discussing a variety of endocrinology related topics.https://consultqd.clevelandclinic.org/?s=pantalone
• Appointed Clinical Assistant Professor of Medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University
• NIH-R01 co-investigator Dynamics of Muscle Mitochondria in Type 2 Diabetes (DYNAMMO T2D).Roles include advising with subject recruitment and advising with the Standard of Care component of the intervention for the type 2 diabetes group and helping with the screening process (2015-2020).
• Chosen by the Endocrine Society to participate in the society’s annual media training seminar (2015) to assist the society with endocrine-related media requests
• Nominated by department leadership to complete the annual “Leading in Health Care” course at Cleveland Clinic, 2015-2016.
• Fellow of the American College of Endocrinologists (FACE), 2015
• Guest Editor, J Am Osteopath Assoc. 2015 Apr 1;115(4_suppl):eS3-eS4.
• Abstract Reviewer, Clinical Diabetes, The Endocrine Society, 2014
• Appointed Director of Clinical Research for the Department of Endocrinology, Diabetes & Metabolism at Cleveland Clinic, August of 2014
• Principal Investigator and Regional Study Leader for DEVOTE: A Trial Comparing Cardiovascular Safety of Insulin Degludec versus Insulin Glargine in Subjects with Type 2 Diabetes at High Risk of Cardiovascular Events
• Authored an online fellow’s module addressing the diagnosis and treatment of male hypogonadism for the American Association of Clinical Endocrinologists, May 2013
• Received national media attention for research pertaining to adverse outcomes with sulfonylurea therapy (The Endocrine Society, U.S. News and World Report, Medscape Medical News, etc.)
• Cleveland Clinic Endocrinology and Metabolism Institute Research Award Winner, Best Research Presentation, April 2011
• Chief Fellow, Department of Endocrinology, Diabetes, and Metabolism, Cleveland Clinic, 2010-2011
• Presidential Poster Competition Winner, The Endocrine Society National Meeting, San Diego, CA, June 2010
• Cleveland Clinic Endocrinology and Metabolism Institute Research Award Winner, Best Research Presentation, April 2010
• Fellow representative for the Cleveland Clinic Diabetes Care Team, a multidisciplinary team of health care providers which meets on a monthly basis to address issues pertaining to diabetes management in the hospital setting, July 2009 to June 2011
• Cleveland Clinic Internal Medicine Senior Resident of the Year, 2008-2009
• Cleveland Clinic Peskind Award, Best Clinical or Nonclinical Paper from a Resident in the Division of Medicine, June 2009
• Cleveland Clinic Resident Research Competition Winner and Internal Medicine Grand Rounds Presentation, Best Internal Medicine Resident Research Project, June 2009
• Graduated in the top 10% at Ohio University College of Osteopathic Medicine, June 2006
• Valedictorian of College of Arts and Sciences, Kent State University, May 2002, GPA 4.0
• Recognized as one of the brightest college students in Northeast Ohio in Northeastern Ohio Live Magazine, May 2002
• Mary Manchester Award for Superior Scholarship, Leadership and Constructive Citizenship, April 2002
• Superior Research Award, Lubrizol Corporation and Kent State University, April 2002
• Phi Beta Kappa National Honors Society, inducted April 2002
• Golden Key National Honors Society, inducted March 2001
• Manuscript Reviewer
• The New England Journal of Medicine, 2014 to present
• The Lancet Diabetes and Endocrinology, 2014 to present
• The Journal of the American Osteopathic Association, 2015 to present
• Diabetes Care, 2017 to present
• The Lancet, 2016 to present
• Acta Endocrinologica, 2019 to present

See publications for this provider. (Disclaimer: This search is powered by PubMed, a service of the U.S. National Library of Medicine. PubMed is a third-party website with no affiliation with Cleveland Clinic.)

Cleveland Clinic physicians and scientists collaborate with industry to advance medical breakthroughs. These partnerships help commercialize discoveries for public benefit while maintaining scientific integrity. To ensure transparency and minimize potential bias, Cleveland Clinic reviews these relationships and publicly discloses when physicians/scientists receive significant compensation for consulting, serve in fiduciary roles, receive royalties, or hold equity interests related to their work. We manage potential conflicts through approval processes, annual reporting, and targeted management plans.

As of 2025-11-05, Dr. Pantalone has reported the financial relationships with the companies listed below.

Consulting and/or Speaking. Dr. Pantalone receives fees of $5,000 or more per year (or, in rare cases, equity or stock options) as a paid consultant, speaker or as a member of an advisory committee for the following companies:

• Eli Lilly and Company
• Bayer Healthcare Pharmaceuticals, Inc.
• Diasome Pharmaceuticals
• Boehringer Ingelheim
• Novo Nordisk, A/S
• Corcept Therapeutics, Inc.
• Sanofi S.A.

Public Health Service-Reportable Financial Conflicts of Interest. Cleveland Clinic scientists and physicians engage in basic, translational and clinical research activities, working to solve health problems, enhance patient care and improve quality of life for patients. Interactions with industry are essential to bringing the researchers' discoveries to the public, but can present the potential for conflicts of interest related to their research activities. Click here to view a listing of instances where Cleveland Clinic has identified a Public Health Service (PHS)-Reportable Financial Conflict of Interest and has put measures in place to ensure that, to the extent possible, the design, conduct and reporting of the research is free from bias.

* Cleveland Clinic physicians and scientists subscribe to the guidance presented in the PhRMA Code on Interactions with Healthcare Professionals and the AdvaMed Code of Ethics on Interactions with Health Care Professionals. As such, gifts of substantial value are generally prohibited.